What is Xilio Therapeutics, Inc.'s earnings per share (EPS)?

Xilio Therapeutics, Inc. (XLO) reported diluted earnings per share of $-4.19 for fiscal year 2025. This represents a 72.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Xilio Therapeutics, Inc. Financials

XLO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Xilio Therapeutics, Inc. (XLO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI XLO FY2025 2026-05-12

External financing and a sharp drop in cash burn became the dominant mechanic behind Xilio’s FY2025 balance-sheet reset.

By FY2025, operating cash burn had fallen to -$5.0M from roughly -$69M two years earlier, a much bigger improvement than the loss line alone implies. Cash still rose to $137.5M because financing inflows added $87.8M; with free cash flow nearly matching operating cash flow, this is an operating-spend business whose cash needs come mainly from research and overhead rather than capital equipment.

R&D spending remained above revenue in FY2025, at $56.0M versus $43.8M, so the larger top line reduced cash pressure without yet covering the core research engine. That matters because the business is still organized around funding development work first and treating reported revenue as a partial offset, not a full operating base.

The balance sheet is liquid in the short term: current assets covered current liabilities by 2.6x. But it is also thinly capitalized, with equity of only $35.3M against total liabilities of $119.4M, so the near-term cushion comes from cash on hand and recent capital raising rather than accumulated profits.

Financial Health Signals

Financial Profile 14/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Xilio Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Xilio Therapeutics, Inc. has an operating margin of -95.9%, meaning the company retains $-96 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -955.0% the prior year.

Leverage

Xilio Therapeutics, Inc. has a moderate D/E ratio of 3.39. This balance of debt and equity financing earns a leverage score of 33/100.

Liquidity

Xilio Therapeutics, Inc.'s current ratio of 2.58 indicates adequate short-term liquidity, earning a score of 48/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Xilio Therapeutics, Inc. generated -$5.0M in operating cash flow, capex of $518K consumed most of it, leaving -$5.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Xilio Therapeutics, Inc. generates a -99.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -330.9% the prior year.

Piotroski F-Score Neutral

4/9

Xilio Therapeutics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.14x

For every $1 of reported earnings, Xilio Therapeutics, Inc. generates $0.14 in operating cash flow (-$5.0M OCF vs -$35.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$43.8M

YoY+589.9%

Xilio Therapeutics, Inc. generated $43.8M in revenue in fiscal year 2025. This represents an increase of 589.9% from the prior year.

EBITDA

-$40.4M

YoY+31.4%

Xilio Therapeutics, Inc.'s EBITDA was -$40.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.4% from the prior year.

Net Income

-$35.0M

YoY+39.8%

Xilio Therapeutics, Inc. reported -$35.0M in net income in fiscal year 2025. This represents an increase of 39.8% from the prior year.

EPS (Diluted)

$-4.19

YoY+72.5%

Xilio Therapeutics, Inc. earned $-4.19 per diluted share (EPS) in fiscal year 2025. This represents an increase of 72.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$5.5M

YoY+70.1%

Xilio Therapeutics, Inc. generated -$5.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 70.1% from the prior year.

Cash & Debt

$137.5M

YoY+148.7%

5Y CAGR+48.2%

Xilio Therapeutics, Inc. held $137.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+38.6%

Xilio Therapeutics, Inc. had 5M shares outstanding in fiscal year 2025. This represents an increase of 38.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-95.9%

YoY+859.0pp

Xilio Therapeutics, Inc.'s operating margin was -95.9% in fiscal year 2025, reflecting core business profitability. This is up 859.0 percentage points from the prior year.

Net Margin

-80.0%

YoY+838.0pp

Xilio Therapeutics, Inc.'s net profit margin was -80.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 838.0 percentage points from the prior year.

Return on Equity

-99.3%

YoY+231.6pp

Xilio Therapeutics, Inc.'s ROE was -99.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 231.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$56.0M

YoY+36.0%

5Y CAGR+5.0%

Xilio Therapeutics, Inc. invested $56.0M in research and development in fiscal year 2025. This represents an increase of 36.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$518K

YoY+1338.9%

5Y CAGR-25.0%

Xilio Therapeutics, Inc. invested $518K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1338.9% from the prior year.

XLO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$43.8M+589.9%	$6.3M	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$56.0M+36.0%	$41.2M-21.0%	$52.1M-11.9%	$59.2M+15.7%	$51.2M+16.6%	$43.9M
SG&A Expenses	$29.7M+19.9%	$24.8M-8.2%	$27.0M-9.9%	$29.9M+25.5%	$23.9M+123.9%	$10.7M
Operating Income	-$42.0M+30.7%	-$60.6M+23.4%	-$79.1M+11.2%	-$89.1M-18.8%	-$75.0M-37.5%	-$54.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$35.0M+39.8%	-$58.2M+23.8%	-$76.4M+13.4%	-$88.2M-16.4%	-$75.8M-37.3%	-$55.2M
EPS (Diluted)	$-4.19+72.5%	$-15.24	$-2.78+13.7%	$-3.22+76.2%	$-13.52	$-105.42

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$12.6M-7.6%	$13.7M-28.2%	$19.1M+135.8%	$8.1M+175.9%	$2.9M	N/A	$2.3M-4.0%	$2.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$19.8M+9.4%	$18.1M+26.5%	$14.3M-6.6%	$15.3M+85.5%	$8.3M	N/A	$10.8M-4.1%	$11.2M
SG&A Expenses	$6.9M-6.4%	$7.4M+10.9%	$6.7M-6.3%	$7.1M-16.4%	$8.5M	N/A	$6.3M+8.5%	$5.8M
Operating Income	-$14.1M-19.2%	-$11.8M-513.6%	-$1.9M+86.6%	-$14.4M-3.7%	-$13.9M	N/A	-$14.8M-0.4%	-$14.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$9.5M-192.0%	$10.4M+163.6%	-$16.3M-2.8%	-$15.8M-19.4%	-$13.3M	N/A	-$14.0M-0.7%	-$13.9M
EPS (Diluted)	$-0.58	N/A	$-0.11+31.3%	$-0.16+93.6%	$-2.49	N/A	$-0.22+8.3%	$-0.24

XLO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$154.7M+117.6%	$71.1M+16.7%	$60.9M-56.2%	$139.2M-36.2%	$218.1M+500.4%	$36.3M
Current Assets	$145.0M+140.8%	$60.2M+25.2%	$48.1M-61.3%	$124.5M-38.5%	$202.5M+883.6%	$20.6M
Cash & Equivalents	$137.5M+148.7%	$55.3M+23.7%	$44.7M-62.9%	$120.4M-39.2%	$198.1M+929.5%	$19.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$119.4M+123.3%	$53.5M+121.9%	$24.1M-28.1%	$33.5M+2.7%	$32.6M-72.7%	$119.6M
Current Liabilities	$56.3M+106.4%	$27.3M+70.8%	$16.0M-24.4%	$21.1M+65.3%	$12.8M-42.3%	$22.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$35.3M+100.4%	$17.6M-52.2%	$36.8M-65.1%	$105.6M-43.0%	$185.4M+322.6%	-$83.3M
Retained Earnings	-$418.8M-9.1%	-$383.8M-17.9%	-$325.5M-30.7%	-$249.1M-54.8%	-$160.9M-89.1%	-$85.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$163.5M+5.7%	$154.7M+15.7%	$133.7M-0.1%	$133.8M+29.0%	$103.7M+45.9%	$71.1M-4.8%	$74.7M-16.9%	$89.9M
Current Assets	$154.2M+6.3%	$145.0M+16.9%	$124.1M+0.3%	$123.7M+32.7%	$93.2M+54.7%	$60.2M-4.9%	$63.3M-18.8%	$78.0M
Cash & Equivalents	$150.3M+9.3%	$137.5M+32.5%	$103.8M-14.6%	$121.6M+36.5%	$89.1M+61.1%	$55.3M-9.7%	$61.3M-18.3%	$74.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$90.9M-23.8%	$119.4M-15.8%	$141.8M+11.9%	$126.7M+36.3%	$93.0M+73.9%	$53.5M-0.4%	$53.7M-4.9%	$56.5M
Current Liabilities	$43.0M-23.7%	$56.3M-0.2%	$56.4M+5.9%	$53.3M+11.8%	$47.6M+74.7%	$27.3M-28.3%	$38.0M-1.6%	$38.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$72.5M+105.7%	$35.3M+535.7%	-$8.1M-214.5%	$7.1M-33.9%	$10.7M-39.2%	$17.6M-16.1%	$21.0M-37.2%	$33.4M
Retained Earnings	-$428.3M-2.3%	-$418.8M+2.4%	-$429.1M-3.9%	-$412.9M-4.0%	-$397.0M-3.5%	-$383.8M-3.5%	-$370.7M-3.9%	-$356.6M

XLO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.0M+72.8%	-$18.4M+73.2%	-$68.6M+9.4%	-$75.7M+6.2%	-$80.8M-123.7%	-$36.1M
Capital Expenditures	$518K+1338.9%	$36K-92.6%	$486K-74.0%	$1.9M+69.7%	$1.1M-49.7%	$2.2M
Free Cash Flow	-$5.5M+70.1%	-$18.4M+73.4%	-$69.1M+10.9%	-$77.6M+5.2%	-$81.9M-113.8%	-$38.3M
Investing Cash Flow	-$518K-1338.9%	-$36K+92.6%	-$486K+74.0%	-$1.9M-69.7%	-$1.1M+49.7%	-$2.2M
Financing Cash Flow	$87.8M+200.6%	$29.2M+545.7%	-$6.5M-9392.8%	-$69K-100.0%	$260.7M+2499.1%	$10.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$22.3M-1018.3%	-$2.0M+88.6%	-$17.5M-20.8%	-$14.5M-150.0%	$29.0M+304.7%	-$14.2M-3.5%	-$13.7M-168.5%	$20.0M
Capital Expenditures	$556K+485.3%	$95K	$0-100.0%	$401K+1722.7%	$22K+266.7%	$6K-33.3%	$9K	N/A
Free Cash Flow	-$22.9M-994.1%	-$2.1M+88.0%	-$17.5M-17.6%	-$14.9M-151.4%	$29.0M+304.4%	-$14.2M-3.5%	-$13.7M	N/A
Investing Cash Flow	-$556K-485.3%	-$95K	$0+100.0%	-$401K-1722.7%	-$22K-266.7%	-$6K+33.3%	-$9K	N/A
Financing Cash Flow	$35.7M-0.4%	$35.9M+12684.6%	-$285K-100.6%	$47.4M+880.2%	$4.8M-41.1%	$8.2M+273500.0%	-$3K-100.0%	$20.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

XLO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-95.9%+859.0pp	-955.0%	N/A	N/A	N/A	N/A
Net Margin	-80.0%+838.0pp	-918.1%	N/A	N/A	N/A	N/A
Return on Equity	-99.3%+231.6pp	-330.9%-123.5pp	-207.5%-124.0pp	-83.5%-42.6pp	-40.9%	N/A
Return on Assets	-22.7%+59.3pp	-81.9%+43.5pp	-125.4%-62.0pp	-63.4%-28.6pp	-34.8%+117.3pp	-152.0%
Current Ratio	2.58+0.4	2.21-0.8	3.02-2.9	5.89-10.0	15.85+14.9	0.93
Debt-to-Equity	3.39+0.3	3.04+2.4	0.65+0.3	0.32+0.1	0.18+1.6	-1.44
FCF Margin	-12.6%+277.7pp	-290.3%	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-111.6%-25.1pp	-86.5%-76.4pp	-10.1%+167.6pp	-177.7%+295.0pp	-472.7%	N/A	-652.3%-28.5pp	-623.8%
Net Margin	-75.3%-151.0pp	75.7%+161.1pp	-85.4%+110.6pp	-196.0%+256.7pp	-452.7%	N/A	-619.5%-28.7pp	-590.8%
Return on Equity	-13.1%-42.5pp	29.4%	N/A	-224.1%-100.2pp	-124.0%	N/A	-66.8%-25.2pp	-41.7%
Return on Assets	-5.8%-12.5pp	6.7%+18.9pp	-12.2%-0.3pp	-11.8%+1.0pp	-12.8%	N/A	-18.8%-3.3pp	-15.5%
Current Ratio	3.59+1.0	2.58+0.4	2.20-0.1	2.32+0.4	1.96-0.3	2.21+0.5	1.67-0.4	2.02
Debt-to-Equity	1.25-2.1	3.39+20.9	-17.52-35.4	17.93+9.2	8.69+5.7	3.04+0.5	2.56+0.9	1.69
FCF Margin	-181.1%-165.8pp	-15.3%+76.5pp	-91.8%+92.3pp	-184.0%-1172.3pp	988.3%	N/A	-604.5%	N/A

Similar Companies

Mersana Therapeutics Inc MRSN

$145.4M

Bioatla, Inc. BCAB

$6.5M

Jasper Therapeutics Inc JSPR

$22.6M

Frequently Asked Questions

What is Xilio Therapeutics, Inc.'s annual revenue?

Xilio Therapeutics, Inc. (XLO) reported $43.8M in total revenue for fiscal year 2025. This represents a 589.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Xilio Therapeutics, Inc.'s revenue growing?

Xilio Therapeutics, Inc. (XLO) revenue grew by 589.9% year-over-year, from $6.3M to $43.8M in fiscal year 2025.

Is Xilio Therapeutics, Inc. profitable?

No, Xilio Therapeutics, Inc. (XLO) reported a net income of -$35.0M in fiscal year 2025, with a net profit margin of -80.0%.

What is Xilio Therapeutics, Inc.'s EBITDA?

Xilio Therapeutics, Inc. (XLO) had EBITDA of -$40.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Xilio Therapeutics, Inc.'s operating margin?

Xilio Therapeutics, Inc. (XLO) had an operating margin of -95.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Xilio Therapeutics, Inc.'s net profit margin?

Xilio Therapeutics, Inc. (XLO) had a net profit margin of -80.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Xilio Therapeutics, Inc.'s return on equity (ROE)?

Xilio Therapeutics, Inc. (XLO) has a return on equity of -99.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Xilio Therapeutics, Inc.'s free cash flow?

Xilio Therapeutics, Inc. (XLO) generated -$5.5M in free cash flow during fiscal year 2025. This represents a 70.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Xilio Therapeutics, Inc.'s operating cash flow?

Xilio Therapeutics, Inc. (XLO) generated -$5.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Xilio Therapeutics, Inc.'s total assets?

Xilio Therapeutics, Inc. (XLO) had $154.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Xilio Therapeutics, Inc.'s capital expenditures?

Xilio Therapeutics, Inc. (XLO) invested $518K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Xilio Therapeutics, Inc. spend on research and development?

Xilio Therapeutics, Inc. (XLO) invested $56.0M in research and development during fiscal year 2025.

How many shares does Xilio Therapeutics, Inc. have outstanding?

Xilio Therapeutics, Inc. (XLO) had 5M shares outstanding as of fiscal year 2025.

What is Xilio Therapeutics, Inc.'s current ratio?

Xilio Therapeutics, Inc. (XLO) had a current ratio of 2.58 as of fiscal year 2025, which is generally considered healthy.

What is Xilio Therapeutics, Inc.'s debt-to-equity ratio?

Xilio Therapeutics, Inc. (XLO) had a debt-to-equity ratio of 3.39 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Xilio Therapeutics, Inc.'s return on assets (ROA)?

Xilio Therapeutics, Inc. (XLO) had a return on assets of -22.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Xilio Therapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Xilio Therapeutics, Inc. (XLO) had $137.5M in cash against an annual operating cash burn of $5.0M. This gives an estimated cash runway of approximately 331 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Xilio Therapeutics, Inc.'s Piotroski F-Score?

Xilio Therapeutics, Inc. (XLO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Xilio Therapeutics, Inc.'s earnings high quality?

Xilio Therapeutics, Inc. (XLO) has an earnings quality ratio of 0.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Xilio Therapeutics, Inc.?

Xilio Therapeutics, Inc. (XLO) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.